JP2010505386A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505386A5
JP2010505386A5 JP2009511025A JP2009511025A JP2010505386A5 JP 2010505386 A5 JP2010505386 A5 JP 2010505386A5 JP 2009511025 A JP2009511025 A JP 2009511025A JP 2009511025 A JP2009511025 A JP 2009511025A JP 2010505386 A5 JP2010505386 A5 JP 2010505386A5
Authority
JP
Japan
Prior art keywords
cycle arrest
cell cycle
induction
cell
cdki protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505386A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/011623 external-priority patent/WO2007133773A2/en
Publication of JP2010505386A publication Critical patent/JP2010505386A/ja
Publication of JP2010505386A5 publication Critical patent/JP2010505386A5/ja
Pending legal-status Critical Current

Links

JP2009511025A 2006-05-15 2007-05-15 Ｃｄｋｉ経路阻害剤の同定 Pending JP2010505386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74721306P 2006-05-15 2006-05-15
PCT/US2007/011623 WO2007133773A2 (en) 2006-05-15 2007-05-15 Identification of cdki pathway inhibitors

Publications (2)

Publication Number Publication Date
JP2010505386A JP2010505386A (ja) 2010-02-25
JP2010505386A5 true JP2010505386A5 (enExample) 2010-07-08

Family

ID=38694544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511025A Pending JP2010505386A (ja) 2006-05-15 2007-05-15 Ｃｄｋｉ経路阻害剤の同定

Country Status (6)

Country Link
US (1) US20080033000A1 (enExample)
EP (1) EP2021019A4 (enExample)
JP (1) JP2010505386A (enExample)
AU (1) AU2007249762A1 (enExample)
CA (1) CA2652341A1 (enExample)
WO (1) WO2007133773A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050165031A1 (en) 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
NZ590355A (en) * 2008-07-10 2013-01-25 Yakult Honsha Kk Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
US20100190807A1 (en) * 2008-08-26 2010-07-29 Senex Biotechnology, Inc. CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
AR086798A1 (es) 2011-06-29 2014-01-22 Otsuka Pharma Co Ltd Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen
EP3431087A1 (en) 2012-02-02 2019-01-23 Senex Biotechnology, Inc. Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer
CA2969974C (en) * 2014-12-15 2020-08-04 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
US11980620B2 (en) 2017-06-08 2024-05-14 The Children's Medical Center Corporation Compounds and methods for treatment of Diamond Blackfan anemia
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
KR20220052333A (ko) * 2019-08-22 2022-04-27 바이오하벤 테라퓨틱스 리미티드 근위축성 측색 경화증 및 관련 장애의 치료를 위한 tdp-43에 결합하는 분자
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9922173D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
JP4934432B2 (ja) * 2004-02-19 2012-05-16 レクサン ファーマシューティカルズ インコーポレイテッド キナゾリン誘導体およびキナゾリン誘導体の治療への使用
EP1748991A1 (en) * 2004-04-28 2007-02-07 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
US8592147B2 (en) * 2005-01-13 2013-11-26 Senex Biotechnology High-content screening for drugs against cancer and age-related diseases

Similar Documents

Publication Publication Date Title
JP2010505386A5 (enExample)
JP2011508438A5 (enExample)
JP2012507448A5 (enExample)
JP2011528458A5 (enExample)
JP2010518805A5 (enExample)
JP2008501714A5 (enExample)
JP2010538767A5 (enExample)
JP2010219032A5 (enExample)
NL2000184A1 (nl) Fiets met vering.
DK2035398T3 (da) Immobiliseret 1,2-benzisothioazolin-3-on
EP2023715A4 (en) Indoleamine-2,3-dioxygenase 2
JP2013508091A5 (enExample)
ATE512132T1 (de) Hydrochloridsalz von 5-ä3-(3- hydroxyphenoxy)azetidin-1-ylü-5-methyl-2,2- diphenylhexanamid
DE602006018127D1 (de) Acetylenderivate
JP2011246422A5 (enExample)
DE602006012689D1 (de) Überprüfungsverfahren
JP2008517002A5 (enExample)
JP2012043586A5 (enExample)
DE602006001668D1 (de) Fehlerüberprüfungsverfahren
JP2006522596A5 (enExample)
DE502006002221D1 (de) Piezoaktor mit innenliegender kontaktierung
NL1030303A1 (nl) Tweewieler.
JP2011249271A5 (enExample)
JP2008545704A5 (enExample)
DE602006003519D1 (de) Aufzeichnungsverfahren